tag@treatmentactiongroup.org

TB

TAGline Spring 2013

  • Chad Cipiti

Advancing Research, Securing Access: Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and two of its insidious comorbidities, viral hepatitis and tuberculosis. Many of these challenges are inextricably intertwined, as we highlight in this issue focusing on specific clinical research and treatment-access hurdles threatening progress for all three diseases.

Read more

Children with Drug-Resistant Tuberculosis Require Urgent Attention

  • Chad Cipiti

Treatment Action Group (TAG), in partnership with the Sentinel Project on Pediatric Drug-Resistant Tuberculosis (Sentinel Project) released today We Can Heal: Prevention, Diagnosis, Treatment, Care and Support: Addressing Drug-Resistant Tuberculosis in Children. This collection, released in anticipation of World TB Day on March 24, calls for urgent attention to the global problem of pediatric drug-resistant tuberculosis (DR-TB).

Read more

TB Zeroes Campaign Achieves Big Win

  • Chad Cipiti

by Erica Lessem The world has recently called for zero new TB deaths, infections, and suffering, and that voice has been heard. Treatment Action Group (TAG), along with other activists, researchers, clinicians, implementers, policy makers, and foundation and government staff…

Read more
TAGline Winter 2013 cover

TAGline Winter 2013

  • Chad Cipiti

Grief Is a Sword: A Eulogy for Spencer Cox; A Global Plan to End AIDS Everywhere but at Home ; On the Edge: Uncertainty Grows over HIV Budgets; Data Deluge at AASLD; Beyond ARVs: Advocacy for Non-AIDS Disease Management; TB Zeroes Campaign Achieves Big Win; TAG Welcomes the FDA Approval of the First New Drug for TB in 40 Years; Help Support Inclusion of Pegylated Interferon on the World Health Organization’s Essential Medicines List; Guide to Clinical Trials for People with Hepatitis C.

Read more

Treatment Action Group Lauds FDA Approval of First New Tuberculosis Drug in Half a Century

  • Chad Cipiti

Treatment Action Group (TAG) applauds the accelerated approval today of bedaquiline, the first new approved drug to treat tuberculosis (TB) in over forty years, by the U.S. Food and Drug Administration (FDA). The drug has the potential to improve the treatment for multi-drug resistant (MDR) TB, a particularly deadly and hard to treat form of TB that affects over a million people worldwide, and from which only about half of patients who are treated recover.

Read more

2012 TAG Update

  • Chad Cipiti

TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.

Read more

Statement on Bedaquiline to the FDA

  • Chad Cipiti

Statement of Mark Harrington, Executive Director, Treatment Action Group to the FDA Anti-Infective Drugs Advisory Committee (AIDAC) Hearing on the Use of Bedaquiline (TMC207) for Treatment of Multidrug-Resistant (MDR) Tuberculosis (TB)

Read more
Back To Top